

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 or 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of September, 2020**

**Commission File Number: 001-38452**

---

**MEREO BIOPHARMA GROUP PLC**

**(Translation of registrant's name into English)**

---

**4th Floor, One Cavendish Place,  
London, W1G 0QE, United Kingdom**  
**(Address of principal executive office)**

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F       Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

---

**Exhibit Index****Exhibits**

99.1 [Press release issued by Mereo BioPharma Group plc "Result of General Meeting" dated September 28, 2020.](#)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: September 28, 2020

**MEREO BIOPHARMA GROUP PLC**

By: /s/ Charles Sermon

Name: Charles Sermon

Title: General Counsel

**Mereo BioPharma Group plc**

("Mereo" or the "Company" or the "Group")

**Result of General Meeting**

**London and Redwood City, Calif., September 28, 2020** - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announces that all five resolutions (the "Resolutions") proposed at the Company's General Meeting ("General Meeting"), held earlier today, were duly passed. The Board is pleased that all the resolutions received strong support from shareholders. Full details of the resolutions can be viewed in the Notice of General Meeting on the Company's website at [www.mereobiopharma.com](http://www.mereobiopharma.com)

The results of the proxy voting in advance of the General Meeting are shown below. On the record date there were 338,713,962 ordinary shares of £0.003 each in issue, each carrying one vote per share.

Resolution	Votes For	Votes at Chairman's Discretion	Votes Against	Votes Withheld	Total Votes Cast	Result
1	129,413,324	0	9,258,138	17,565	138,689,027	Passed
2	138,317,100	0	178,850	193,077	138,689,027	Passed
3	138,558,837	0	92,945	37,245	138,689,027	Passed
4	125,187,297	0	13,290,680	211,050	138,689,027	Passed
5	124,695,799	0	13,216,200	777,028	138,689,027	Passed

**About Mereo BioPharma**

Mereo BioPharma is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Mereo's lead oncology product candidate, etigilimab (Anti-TIGIT), has completed a Phase 1a dose escalation clinical trial in patients with advanced solid tumors and has been evaluated in a Phase 1b study in combination with nivolumab in select tumor types. Mereo's rare disease product portfolio consists of setrusumab, which has completed a Phase 2b dose-ranging study in adults with osteogenesis imperfecta (OI), as well as alvelestat, which is being investigated in a Phase 2 proof-of-concept clinical trial in patients with alpha-1 antitrypsin deficiency (AATD) and in a Phase 1b/2 clinical trial in COVID-19 respiratory disease.

**Mereo BioPharma Contacts:**

**Mereo** +44 (0)333 023 7300

Denise Scots-Knight, Chief Executive Officer

**N+1 Singer (Nominated Adviser and Broker to Mereo)** +44 (0)20 7496 3081

Phil Davies

Will Goode

---

**Burns McClellan (US Investor Relations Adviser to Mereo)**

**+01 212 213 0006**

Lisa Burns

Steve Klass

**FTI Consulting (UK Public Relations Adviser to Mereo)**

**+44 (0)20 3727 1000**

Simon Conway

Ciara Martin

**Investors**

[investors@mereobiopharma.com](mailto:investors@mereobiopharma.com)